{"date":"2026-10-03","count":3,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6461-2026-10-03-1814-15knxpi","company_id":"6461","company":"益得","market":"上櫃","industry":"生技醫療","date":"2026-10-03","time":"18:14:46","subject":"公告本公司115年限制員工權利新股第一次發行之增資基準日","clause":"第53款","fact_date":"2026-10-03","cite_as":"公開資訊觀測站重大訊息：益得（6461），2026-10-03 18:14，「公告本公司115年限制員工權利新股第一次發行之增資基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7827-2026-10-03-1700-14b5v4q","company_id":"7827","company":"漢康-KY創","market":"上市","industry":"生技醫療","date":"2026-10-03","time":"17:00:54","subject":"代子公司FBD Biologics Limited公告，HCB303美國新藥臨床試驗申請（IND）獲准進行臨床試驗","clause":"第10款","fact_date":"2026-10-03","cite_as":"公開資訊觀測站重大訊息：漢康-KY創（7827），2026-10-03 17:00，「代子公司FBD Biologics Limited公告，HCB303美國新藥臨床試驗申請（IND）獲准進行臨床試驗」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7754-2026-10-03-0847-1prxhfv","company_id":"7754","company":"安基生技","market":"興櫃","industry":"生技醫療","date":"2026-10-03","time":"08:47:50","subject":"公告本公司開發中新藥AJ201於美國開展甘迺迪氏症病患之第三期臨床試驗。","clause":"第8款","fact_date":"2026-10-03","cite_as":"公開資訊觀測站重大訊息：安基生技（7754），2026-10-03 08:47，「公告本公司開發中新藥AJ201於美國開展甘迺迪氏症病患之第三期臨床試驗。」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}